BML Capital Management LLC Raises Stock Holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA)

BML Capital Management LLC lifted its holdings in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 269,839 shares of the company’s stock after buying an additional 26,000 shares during the quarter. Lisata Therapeutics makes up about 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th biggest position. BML Capital Management LLC’s holdings in Lisata Therapeutics were worth $737,000 as of its most recent SEC filing.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a report on Friday, March 1st.

Lisata Therapeutics Stock Down 0.7 %

LSTA opened at $2.65 on Wednesday. The stock’s fifty day moving average is $3.03 and its two-hundred day moving average is $2.71. The company has a market capitalization of $22.01 million, a P/E ratio of -1.03 and a beta of 1.04. Lisata Therapeutics, Inc. has a 52 week low of $1.95 and a 52 week high of $4.53.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.20. Equities analysts anticipate that Lisata Therapeutics, Inc. will post -3.08 earnings per share for the current year.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.